James Perry

Dr. Perry is a clinician-investigator interested in the design, conduct and analysis of clinical trials testing innovative therapies for primary brain tumours. His research unit is focused on outcomes research. He is the chair of the Canadian Brain Tumour Consortium (CBTC), a national not-for-profit investigator network. He has held leadership roles in the following international collaborative clinical trials:

• PRODIGE trial: an international, Phase 3 randomized controlled trial testing the safety and efficacy of long-term thromboprophylaxis in patients with malignant glioma. Dr. Perry was the global principal investigator (PI) and heads the steering committee.
• RESCUE study: a trial testing low-dose protracted temozolomide chemotherapy in recurrent brain tumours. He is the PI for this study.
• NCIC-CTG CE6 study of treatment for elderly patients with glioblastoma. Perry is the global co-PI.

Education

• B.Sc. (Hons), 1985, University of Toronto, Canada
• MD, 1989, U of T, Canada
• FRCPC, 1993, neurology
• Diploma in clinical epidemiology, U of T
• Neuro-oncology fellowship, Duke University, North Carolina

Appointments and Affiliations

• Affiliate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
• Professor, department of medicine, division of neurology, U of T
• Tony Crolla Chair in Brain Tumour Research
• Chairman, Canadian Brain Tumour Consortium